Developing sustainable antiviral treatments for global protection against infection
Antiviral treatments have been notoriously difficult due to the virus tendency to evolve.
Recent pandemics have exposed the world's vulnerability to infectious diseases. COVID-19 is the fifth pandemic, after SARS (2003), H1N1 (2010), MERS (2011), and Zika (2015). Benevira has been focused on discovering innovative therapeutics to meet the global need of supplying antivirals to everyone.
Challenging science in a transformative way, Benevira is developing sustainable therapeutics by targeting the viral evolutionary bottlenecks.
WHO WE ARE
Benevira is a global, privately owned synthetic biology company focusing on stopping the spread of global viral epidemics and getting ahead of potential outbreaks.
Our team continues to develop and manufacture biologics, therapeutics, and consumer health products for patients across the globe.
WHAT WE DO
Our product portfolio is based on an innovative technology that allows for the development of therapeutics and prophylactics for viral indications such as SARS-CoV-2, SARS-CoV-1, HPV, RSV, MERS, Variola, and Influenza.
The same technology can support development of broad spectrum antivirals.